Skincare brand Numour in talks to raise $3.1 Mn

Did Sharpe already invest in Naturis or is this the same news twice?

No, these are two separate deals, not the same announcement twice. In July 2026, Sharrp Ventures led a ₹100 crore investment in Naturis Cosmetics, a contract manufacturer, the company's first institutional funding since its 2011 founding. The newer report, from September 2026, says Naturis is in talks for a fresh ₹30 crore round, also led by Sharrp, on top of the completed July round.

Why is a family office pouring money into a factory instead of brand names?

Sharrp has no fixed exit compulsions and can hold investments until an IPO (initial public offering, when a company lists on a stock exchange) or acquisition makes sense. It sees Naturis as the durable layer behind the D2C beauty wave, with ₹154 crore in FY25 revenue and 40% growth. Our read: it bets on manufacturing that compounds rather than on fashion-driven brands.

What makes a factory worth 40 times earnings?

The July round priced Naturis at roughly ₹364 crore on ₹154 crore of FY25 revenue and ₹12 crore of profit, or about 30 times earnings. The premium reflects growth more than current profit: revenue climbed 40% in a year, the firm holds 50-plus brand clients, and the Mariwala family office expects compounding rather than quick exits. Our read: the valuation prices a factory that can add categories and export markets, not one that already delivers them.

What could break the bet that a contract manufacturer keeps compounding?

The bet rests on a 7.7% net margin earned across 50-plus brand clients while revenue grew 40% in FY25. Sharrp is expanding Naturis into men's grooming, colour cosmetics, fragrances and exports all at once, and adding new clients like the launch of lines for North America. The risk is that each new category and market demands its own formulation and regulatory work, which can thin margins before volumes scale. Our read: the deal fails if Naturis grows sales faster than its profitability, because the 30-times-earnings price was justified by compounding, not by today's profit.

What protects the factory if its big brand clients jump ship?

Naturis serves 50-plus brands, but the client list is what makes the margin thin: Nykaa, Plum, Pilgrim and Bare Anatomy can each switch manufacturers, so Naturis cannot hold them captive. Its moat is the opposite of a brand's: a 100,000-square-foot plant, 250-plus staff and a 12-year record of turnkey formulation-to-shelf service give clients cost and speed reasons to stay, not loyalty. Our read: Naturis wins by being the cheapest reliable option, which is why adding clients and categories matters more than defending any one of them.

What does the investor gain by backing the same factory twice?

Sharrp's July round bought a 6.19% stake in Naturis for ₹22.5 crore, and the new ₹30 crore round would add to that position. The family office has no fixed exit compulsions, so it can keep funding a company across multiple rounds rather than forcing an early exit. This is the same pattern that produced its 66% IRR on unlisted investments: hold early positions in consumer names like Nykaa and Mamaearth until they go public. Our read: the second cheque is about deepening ownership of the manufacturing layer before its value compounds, not rescuing a struggling company.

What happens if the factory's new categories and exports never scale up?

The fresh round is priced on the same 30-times-earnings logic as July: Naturis must keep compounding revenue and profit together. If men's grooming, colour cosmetics, fragrances and the North America launch grow slower than expected, the margin thinning risk the deal already carries turns into a valuation problem for the next round. With no fixed exit compulsions, Sharrp can hold through a miss, but the 66% IRR record depends on exits like the Nykaa and Mamaearth IPOs. Our read: a stalled expansion forces a longer hold, not a write-off, because Sharrp's structure tolerates patience that other funds cannot afford.

What would force Sharrp to sell before the factory matures?

Sharrp's deal for Naturis carries no fixed exit compulsions, so nothing in the round itself forces a sale. The family office manages only its own capital with no external limited partners, meaning no quarterly performance pressure and no fund life that would demand a mark-up or exit. Our read: only a need for liquidity at the family level, not the investment structure, would push a sale before the manufacturing bet compounds, because Sharrp's patience is built into its ownership model.

Can owning the factory squeeze out more profit for the investor?

Naturis earned a 7.7% net margin in FY25. Backward integration, meaning owning the manufacturing itself, lets the investor capture supplier margins and control costs, but it risks thinning that margin if expansion spreads too thin. Watch whether Naturis can grow sales without cutting into its profitability.

What is the new September story about?

The September news is that India's Sharrp Ventures, the investment arm of the Mariwala family (founders of consumer goods company Marico), is in talks to put about ₹30 crore into Naturis Cosmetics, a contract manufacturer making beauty products for 50+ brands. This would be a fresh tranche on top of the ₹100 crore round Sharrp led in July 2026.

What happens to Naturis if one of its big brand clients stops buying?

Naturis spreads that risk by serving 50-plus brands, including Nykaa, Plum, Pilgrim and Bare Anatomy, plus OTC products for Glenmark and Dr. Reddy's. No single client is essential, and its 40% revenue growth in FY25 suggests the base is widening. But its 7.7% net margin leaves little room to absorb a large order loss without cutting into profit. Our read: the client spread, not the factory, is what protects the margin.

Can the factory grow without hurting its thin profit margin?

The ₹100 crore July round is being asked to fund new categories: men's grooming, body care, colour cosmetics, fragrances and exports. Each new line needs its own R&D, packaging and regulatory work, and the 100,000 square foot Jammu plant is the asset that must carry all of it. Naturis reached ₹154 crore in FY25 at a 7.7% net margin, so any misstep on cost control shows up fast. Our read: expansion will compress the margin before it recovers, and Sharrp's patient capital is what lets Naturis absorb that dip without panicking.

Why does a thin profit margin make adding new product lines risky?

Each new category, whether men's grooming, body care, colour cosmetics or fragrances, needs its own R&D, packaging and regulatory approvals before a single unit sells. Those costs land upfront while revenue from the new line builds slowly, which is why the 7.7% net margin is the constraint. Naturis earned ₹154 crore in FY25 at that margin, so a heavy cost year in expansion directly shaves the profit figure that justified the investment. Our read: the margin will dip in the next year or two before new lines start paying for themselves.

What happens to Sharrp's plan if the margin dips too far?

Sharrp has no external investors and no fixed exit timeline, so it can hold Naturis through a margin dip without pressure to sell or mark up. It has roughly ₹750 crore deployed across 40 companies and aims to invest ₹125-150 crore annually, so this round is within its normal ticket size. Our read: Sharrp is betting the margin recovers after expansion, and its patient capital is what makes that wait affordable.

Why would Sharrp back a brand on top of the factory it already owns?

Sharrp's model is to stay in consumer sectors it understands and hold through multiple rounds. It already owns 6.19% of Naturis after the July round, and this $3.1 million ticket is within its normal $1-3 million range. Backing Numour lets Sharrp cover both ends of the chain: the manufacturer and one of the brands it could serve. Our read: the two bets reinforce each other, since a growing brand base feeds the factory's 40% growth.

Does owning the factory protect Sharrp if the beauty boom slows?

Backward integration, owning the manufacturing layer, is about control: securing supply, capturing supplier margin, and controlling cost rather than betting on any single brand's fate. Naturis spreads demand risk across 50-plus clients, and Sharrp holds it as a growth-stage asset inside a portfolio that has already seen Nykaa and Mamaearth go public. Our read: the factory is the hedge, not the bet, and Sharrp is paying for the right to own the margin when demand firms up again.

Why raise ₹30 crore two months after ₹100 crore?

Naturis, a manufacturer of beauty products for 50+ brands, raised ₹100 crore in July from Sharrp Ventures, its first ever funding since 2011. Two months later, Sharrp is in talks to add a smaller ₹30 crore round. The family office sees a profitable, growing factory behind the D2C beauty wave, and it has the patient capital to keep adding to that bet.

What is the money for, if not new brands?

The cash is meant to accelerate Naturis' existing operations, which already serve over 50 brands including Nykaa, Plum and Pilgrim, not to fund new brands. The July round valued it at around ₹364 crore and gave Sharrp a 6.19% stake. Naturis makes skincare, haircare, makeup and even OTC products for drugmakers. Our read: the third-round addition buys capacity and expansion across categories and exports, betting that the factory's growth outpaces any single brand it serves.

How much does owning the factory actually reduce a brand's costs?

The evidence does not break out the margin Naturis earns for the holding investor. What is known: Naturis reported a 7.7% net margin in FY25, and reports flag that expanding across men's grooming, body care, colour cosmetics, fragrances and exports at once risks thinning that margin. Backward integration lets the investor capture supplier margins, but the factory's own profitability stays the binding constraint. Our read: the cost saving shows up in Naturis's margin, not in price cuts to the brands that buy from it.

What does owning the factory change for the brands that buy from it?

Naturis works as a contract manufacturer for 50+ brands, offering end-to-end services from formulation to packaging, with a 100,000 square foot facility in Jammu housing its R&D and QA labs. For brands like Nykaa and Plum, the factory is their supplier, not their owner; Naturis's own profitability, not price cuts, absorbs the economics of integration. Our read: Sharrp's investment makes Naturis a stronger, more capable partner, but the brands still pay market rates for what it makes.

If the factory is already profitable, why does it need investor money at all?

Naturis turned profitable on roughly ₹154 crore in FY25 revenue, but the new capital is earmarked for expansion, not repair. The July filing shows funds going to accelerate operations, and reports flag simultaneous pushes into men's grooming, body care, colour cosmetics, fragrances and exports. Growing all those lines at once is capital-hungry, and the 100,000 square foot Jammu facility may need capacity and R&D upgrades to serve more brands. Our read: the money buys speed, letting Naturis capture these new categories before competitors do.

If the factory stays profitable, where does the extra money actually go?

The new capital is earmarked for expansion, and reports flag simultaneous pushes into men's grooming, body care, colour cosmetics, fragrances and exports. The Jammu facility is a 100,000 square foot plant housing production, R&D and QA labs, and growing those categories at once means adding capacity and product lines. Sharrp's aim of investing up to ₹150 crore annually in consumer businesses suggests this is the kind of bet it makes repeatedly. Our read: the money funds new production lines and export capacity, not higher payouts to the founders or brands.

What stops the factory from just raising prices to protect its margin?

Naturis operates as a contract manufacturer, and its clients include large brands like Nykaa, Plum and Pilgrim that can source elsewhere, plus OTC clients like Glenmark and Dr. Reddy's. Its 7.7% net margin reflects what the market will pay for its formulation, packaging and regulatory services, not what the investor wants. The 100,000 square foot Jammu facility competes on quality and speed. Our read: raising prices would push brands to rival manufacturers, so margin protection comes from volume and efficiency, not pricing power.